"NICE's initial 'no' to approving risdiplam for NHS funding is not unexpected ... who cannot have the other SMA treatment options. Spinraza was also rejected by NICE in the first instance ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Additional pressure was then placed on the brand when Roche launched its daily oral therapy Evrysdi (risdiplam) towards the end of that year at a discount to Biogen's injectable rival. Spinraza ...

Chris Towler, who is 25, has type 3 SMA and is one of many who could potentially benefit from risdiplam. In the past two years he has lost the ability to walk while waiting for Spinraza.

Nusinersen (Spinraza) is an injection, which can be used to treat both adults and children, and risdiplam (Evrysdi), which is a small molecule also used to treat both adults and children. He said that ...

Nusinersen (Spinraza) (used to treat both adults and children), and Risdiplam (Evrysdi) is a small molecule which is also used to treat both adults and children. However, the cost of these ...